Bondi is on the clock

The TDR Morning Narrative

Note: Cannabis Confidential is shifting content strategy in 2026 with more insights from trusted partners, industry insiders, and corporate leaders who’ve got something to say—and now a place to say it. There will be no more paywalls or content fees; think of it as The Players Tribune for the cannabis industry, with an ethos of honesty, trust and respect.

I will continue to share real-time insights daily on X-subs, which costs less than what a monthly fee was for Substack—and it’s real-time—so if you enjoy and are in a position to support those efforts, I sure would appreciate it as we ready for a year to remember.

💸 The Tape, by TDR

Sara Carter is the newly confirmed Director of the White House Office of National Drug Control Policy (ONDCP)—the job more commonly known as “drug czar,” a title that sounds like it comes with a scepter but mostly comes with interagency meetings, strategy documents, and a very large overdose-and-trafficking problem to manage.

The Senate confirmed Carter January 6, 2026 as the country’s 10th ONDCP Director.

So who is she? Carter is best known as an investigative journalist whose work has focused heavily on border security, drug trafficking networks, and national security themes—often emphasizing the mechanics of cartel logistics and the downstream impact on American communities.

Outlets covering her confirmation and background have consistently framed her as a long-tenured reporter with extensive on-the-ground exposure to trafficking dynamics, rather than a career public-health or law-enforcement official.

That unusual résumé is also the core argument for why she’s in the chair.

At her confirmation hearing, Carter directly addressed the “you’re not a clinician” critique with a blunt inventory of what she is not—then anchored her case in firsthand field reporting and sustained attention to cartel and trafficking ecosystems.

In an era where fentanyl supply chains behave less like isolated criminal enterprises and more like adaptive networks, the administration’s bet is straightforward: put someone in charge who has spent years studying those networks, talking to sources in and around them, and translating messy realities into a narrative decision-makers will actually read.

More Info……

Where things get more interesting—especially for cannabis audiences—is Carter’s posture on medical marijuana. Reporting on her nomination and confirmation notes that she has expressed support for medical cannabis access, and has also said she doesn’t have a “problem” with legalization if it is monitored, even if she might not personally align with the policy preference.

In other words, she’s not arriving with the rhetorical reflex to treat all cannabis policy as a moral referendum. She has framed medical marijuana as a pragmatic tool for patients—particularly in serious illness contexts—while keeping her public emphasis on fentanyl, opioids, and transnational trafficking as the main threat set.

Why does that matter? Because the ONDCP director’s job is not just enforcement theater; it is coordination—aligning agencies, budgets, and strategy across public health, interdiction, prevention, treatment, and international cooperation.

A director who can simultaneously acknowledge medical cannabis as legitimate for patients, while pursuing an aggressive anti-fentanyl agenda, potentially lowers the odds of policy incoherence—where resources and messaging collide in public, and outcomes suffer in private.

The mildly witty takeaway: Carter is not the “drug czar” because she’s spent a lifetime in government; she’s the “drug czar” because she’s spent a lifetime watching the drug war’s supply lines up close and the White House is wagering that field instincts, media discipline, and cartel fluency will translate into better coordination at the center of U.S. drug policy.

This is Third-Party content and does not reflect (or not not reflect) the views of Cannabis Confidential or CB1 Capital.